IMM 11.9% 29.5¢ immutep limited

Overnight Market report, page-962

  1. 56 Posts.
    lightbulb Created with Sketch. 45
    you guys need to wind down the wishful thinking. To get a marketing authorisation on ph2 data you need to be running a ph3. Read the latest quarterly- aipac ph3 is not a priority and neither is the MA - and rightly so. As an investor you dont want them to sink 50-100m into a ph3 that has a high chance of missing the mark or being redundant due to new drug advancements. Treatment landscape for mbc is changing rapidly so sample population from ph2 will not be the same in ph3 which means you have a high risk of ph2 data not extrapolating into ph3 (just like we say with ph1 and ph2 of aipac).
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
(20min delay)
Last
29.5¢
Change
-0.040(11.9%)
Mkt cap ! $428.5M
Open High Low Value Volume
32.0¢ 33.0¢ 28.0¢ $7.278M 23.75M

Buyers (Bids)

No. Vol. Price($)
4 53192 29.5¢
 

Sellers (Offers)

Price($) Vol. No.
30.5¢ 41048 1
View Market Depth
Last trade - 16.10pm 28/06/2024 (20 minute delay) ?
IMM (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.